Commercialization of a cell-manufacturing process optimization service - Lab2Market (Market assessment)

细胞制造工艺优化服务的商业化 - Lab2Market（市场评估）

• 批准号: 571234-2022
• 负责人: Ungrin, Mark
• 金额: $ 1.46万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=729088
• 关键词: Commercialization; cell; manufacturing; process; optimization

Cell-based therapies are poised to revolutionize healthcare around the world. Promising to cure chronic diseases, and fully repair damaged tissues and organs, demand for these treatments will be tremendous - as will the costs. While the first few cell-based treatments have entered Canadian health care market, the massive price tag serves as a bottleneck for the uptake of treatments by doctors, patents and the government. In some cases, the cost-of-goods alone for cell manufacturing is estimated to be in the tens and even hundreds of thousands of dollars per dose per patient. Effective, curative treatments may not see the light of day if they are not economically viable. The cost of cell manufacturing must come down to make cell therapies accessible. Over the past several years, we have engineered a biomedical platform integrating scalable cell culture, advanced statistical methods and Machine Learning, and robotic systems to systematically optimize cell manufacturing processes, making them cheaper, faster, and more robust. Our secondary market research indicates a strong need for the cell manufacturing process optimization service. The requested funds for a Market Assessment via a Lab 2 Market program will allow us to focus on primary market research to confirm, expand, or disprove our marketing plan assumptions, and to develop a detailed strategy for the commercialization of our platform.

细胞疗法有望彻底改变世界各地的医疗保健。这些疗法有望治愈慢性疾病，并完全修复受损的组织和器官，对它们的需求将是巨大的——成本也是如此。虽然最初的几种细胞疗法已经进入加拿大的医疗保健市场，但高昂的价格成为医生、专利和政府接受这种疗法的瓶颈。在某些情况下，单是制造细胞的成本估计就高达每位患者每剂数万甚至数十万美元。如果在经济上不可行，有效的、治愈性的治疗方法可能看不到曙光。细胞制造的成本必须降低，才能使细胞疗法变得可行。在过去的几年里，我们设计了一个生物医学平台，集成了可扩展的细胞培养，先进的统计方法和机器学习，以及机器人系统，以系统地优化细胞制造过程，使其更便宜，更快，更强大。我们的二级市场研究表明，对电池制造过程优化服务的强烈需求。通过实验室2市场计划进行市场评估所需的资金将使我们能够专注于主要的市场研究，以确认、扩展或反驳我们的营销计划假设，并为我们的平台的商业化制定详细的战略。